MM&M2d
Rx Rundown: Merck, Biogen, Pfizer and more
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
HC Wainwright Reiterates “Buy” Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a ...
BioPharma Dive4d
BioAge drops obesity drug; Akero, 89bio cash in on MASH data
BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.
H.C. Wainwright maintains $18 target on Vanda Pharmaceuticals stock
H.C. Wainwright reaffirmed their positive stance on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy rating and a price target of $18.00, representing significant upside potential from the current price ...
A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a ...
Vanda Pharmaceuticals: Buy Rating Affirmed Amidst Pipeline Progress and Strategic Expansion
Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vanda (VNDA – Research Report) and keeping the price target at ...
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com
Research analysts at StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on ...
D.C.'s Vanda Pharmaceuticals battling FDA on multiple fronts
A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic ...
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed through a social media post ...
Vanda Pharmaceuticals accepts FDA opportunity for a hearing in tradipitant NDA
Vanda Pharmaceuticals (VNDA) provided an update on the tradipitant development program. Gastroparesis is a serious digestive disorder of the ...
BioWorld9d
US Claims Court rules Vanda’s trade secrets not so secret
A U.S. Federal Claims Court judge shot down Vanda Pharmaceuticals Inc.’s accusations that the FDA disclosed the company’s ...
Pharmaceutical Technology14d
VHX-896 by Vanda Pharmaceuticals for Schizophrenia: Likelihood of Approval
VHX-896 is under clinical development by Vanda Pharmaceuticals and currently in Phase III for Schizophrenia. According to GlobalData, Phase III drugs for Schizophrenia have a 68% phase transition ...